Zymeworks Inc. 8-K

What Happened

• On May 14, 2026, Zymeworks Inc. (ZYME) filed an 8-K announcing that its Board authorized a new 2026 Share Repurchase Program to buy up to $125.0 million of common stock. The Board also terminated the prior 2025 Repurchase Program, under which the company repurchased 4,197,553 shares at an average price of $24.36 per share for aggregate repurchases of $102.3 million (excluding commission and estimated excise tax).
• In a Regulation FD disclosure portion of the filing, Zymeworks said that, based on current operating plans and assuming full execution of the $125.0 million repurchase program, its existing cash as of March 31, 2026 plus anticipated regulatory milestone payments of $440.0 million tied to potential approvals of Ziihera in the U.S., Europe, Japan and China are expected to fund planned operations beyond 2028. The company noted this projection excludes any additional future milestones, royalties, other licensed candidates, or future collaborations.

Key Details

• Board action date: May 14, 2026; press release attached as Exhibit 99.1.
• New repurchase authorization: up to $125.0 million of common stock.
• Prior repurchases (2025 program): 4,197,553 shares repurchased for $102.3 million total; average price $24.36/share.
• Cash runway statement: existing cash (as of Mar 31, 2026) + $440.0 million in anticipated Ziihera regulatory milestones projected to fund operations beyond 2028 (assumes full execution of repurchase plan).

Why It Matters

• Share repurchase programs reduce outstanding shares and can support the stock price or return capital to shareholders; the new $125M program signals the Board’s intent to use cash for buybacks.
• The company’s disclosure about cash runway gives investors a timeline for how long operations may be funded under current plans and key assumptions (including large milestone payments tied to Ziihera approvals). Investors should note the runway depends on expected milestone payments and does not include potential additional revenue streams.